Year in Review by Dr. Cush and Dr. Kavanaugh Combo biologic therapy? Phase II study from GI colleagues for UC Guselkumab + golimumab - no additional safety concerns - improved clinical response - extrapolate to rheumatology use? #RNL2023 @RheumNow https://t.co/DirAovm1AX